Please wait while we take you to your selected region.
Tesamorelin is a synthetic 44–amino acid peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to increase natural growth hormone secretion.
It is FDA-approved for treating HIV-associated lipodystrophy, where it helps reduce abnormal abdominal fat accumulation. It is also being studied for potential effects on metabolism, cognitive function, and nerve repair, but many of these applications remain investigational.
People with HIV have a higher risk of heart disease, partly due to abnormal fat buildup and the effects of HIV medications. Tesamorelin not only reduces excess fat but also lowers triglyceride levels, total cholesterol, and other harmful fats in the blood. Reducing fat in the abdomen by 15% with tesamorelin can lead to a significant drop in triglyceride levels. Excess fat in areas like the abdomen, liver, or around the heart also causes inflammation, which increases heart disease risk. By reducing this fat, tesamorelin lowers inflammation and heart disease risk.
HIV treatments can disrupt hormone levels, leading to growth hormone deficiency in about one-third of HIV patients on these therapies. This deficiency may contribute to fat buildup in lipodystrophy. Tesamorelin is a safer and more effective way to boost growth hormone levels compared to directly administering growth hormone, especially for people with HIV.
Peripheral nerve damage, caused by injury, diabetes, or surgery, can lead to problems with movement and sensation. Nerve cells are hard to repair, but tesamorelin shows promise in speeding up and improving nerve healing, making it a leading candidate for further research in this area.
Early research suggests tesamorelin may help improve memory in people with early-stage dementia. A major study found that tesamorelin and similar peptides can increase levels of a brain chemical (GABA) and decrease another (myo-inositol), which may help protect brain function. This opens the door to using tesamorelin for dementia treatment and sparks new ideas for research into preventing or curing dementia.
Since tesamorelin is already FDA-approved for HIV-associated lipodystrophy, it's a strong candidate for further studies. Researchers are exploring its potential to reduce heart disease risk in HIV patients, improve nerve repair after injury, and slow dementia progression. Clinical trials are underway to investigate these possibilities.